BBOT
Financials
- Market Capitalization 700.72 M
- Employee 88
- Founded 2016
- CEO N/A
- Website www.bridgebio.com
- Headquarter Delaware, United States
- FIGI BBG01L3GYF02
- Industry Biotechnology
Related tickers
| # | Name | Price | 24h % | 7d % | 1M % | 1Y % | Market Cap | Last 7 Days | |
|---|---|---|---|---|---|---|---|---|---|
| 2677 |  NGNE Neurogene Inc. - Common Stock | 36.58 USD | -3.38% | -5.33% | +8.71% | +24.34% | 732.02 M USD | ||
| 2697 |  STTK Shattuck Labs, Inc. - Common Stock | 7.04 USD | -7.97% | -8.09% | +2.77% | +611.11% | 706.56 M USD | ||
| 2705 |  CTMX CytomX Therapeutics, Inc. - Common Stock | 3.21 USD | -6.14% | -2.73% | +0.94% | +58.91% | 699.46 M USD | ||
| 2706 |  ALLO Allogene Therapeutics, Inc. - Common Stock | 2.02 USD | -3.35% | -4.27% | +8.60% | +80.36% | 697.89 M USD |
Frequently asked questions about BridgeBio Oncology Therapeutics, Inc. Common Stock
What is the BridgeBio Oncology Therapeutics, Inc. Common Stock stock price today?
The current price of BridgeBio Oncology Therapeutics, Inc. Common Stock (BBOT) is 8.74. Over the past 24 hours, the stock has changed by -4.79%. Follow the BBOT chart for real-time price dynamics.
What is the stock ticker of BridgeBio Oncology Therapeutics, Inc. Common Stock?
BridgeBio Oncology Therapeutics, Inc. Common Stock trades under the ticker BBOT. Tickers can differ by exchange, so always check the exchange and instrument details before trading.
Is BridgeBio Oncology Therapeutics, Inc. Common Stock stock going up?
BBOT has changed by -0.91% over the last week, +5.68% over the last month, and -3.10% over the last year. Review the chart to see whether the current move is part of a broader trend.
What is the market capitalization of BridgeBio Oncology Therapeutics, Inc. Common Stock?
BridgeBio Oncology Therapeutics, Inc. Common Stock currently has a market capitalization of 700.72 M. Market capitalization reflects the total market value of a company's outstanding shares and is commonly used to compare companies by size.
What were BridgeBio Oncology Therapeutics, Inc. Common Stock earnings last quarter?
Last quarter, BridgeBio Oncology Therapeutics, Inc. Common Stock reported earnings of -705.2 per share. Earnings per share is one of the key metrics investors use to evaluate a company's profitability and financial performance.
What was BridgeBio Oncology Therapeutics, Inc. Common Stock revenue for the last quarter?
BridgeBio Oncology Therapeutics, Inc. Common Stock reported quarterly revenue of 3.55 M. Revenue is one of the main indicators used to evaluate the company's business growth and operating scale.
What was BridgeBio Oncology Therapeutics, Inc. Common Stock net income for the last quarter?
BridgeBio Oncology Therapeutics, Inc. Common Stock reported net income of -56.45 M for the last quarter. The previous quarter showed -42.11 M, which means net income changed by -34.08%.
How many employees does BridgeBio Oncology Therapeutics, Inc. Common Stock have?
As of the latest available data, BridgeBio Oncology Therapeutics, Inc. Common Stock has 88 employees. Workforce size can provide additional context about the company's scale and operations.
What is BridgeBio Oncology Therapeutics, Inc. Common Stock EBITDA?
BridgeBio Oncology Therapeutics, Inc. Common Stock EBITDA is -56.02 M, and its EBITDA margin is -1 577.47%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.
How can I buy BridgeBio Oncology Therapeutics, Inc. Common Stock stock?
You can buy BridgeBio Oncology Therapeutics, Inc. Common Stock (BBOT) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.
Should I invest in BridgeBio Oncology Therapeutics, Inc. Common Stock stock?
Investing in BridgeBio Oncology Therapeutics, Inc. Common Stock requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the BBOT chart and related analysis on metatrader.com as part of your research.